All News
RA Patients on Biologics and tsDMARDs are still High Risk
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
Read Article
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
Read Article
Clinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Read Article
Disease activity increases the risk of future RA-ILD. For every one point increase in DAS28, theres a 35% increase risk of RA-ILD @jeffsparks @UTSW_Rheum https://t.co/P3dNDVanuL
Dr. John Cush RheumNow ( View Tweet)
MUC5B is a common genetic variant (~12%) that is strongly assoc w/ IPF, but also RA-ILD (3.1-4.7 fold risk) @jeffsparks @UTSW_Rheum https://t.co/t1Kgmj8a3x
Dr. John Cush RheumNow ( View Tweet)
Survival in RA-ILD is reduced (data from two different eras) @jeffsparks @UTSW_Rheum https://t.co/7eGgGnEgwW
Dr. John Cush RheumNow ( View Tweet)
Risk of RA-ILD is 15% (or 1 in 6) according to Mayo clinic (Olmstead county) data. @jeffsparks https://t.co/KynitLCsK7
Dr. John Cush RheumNow ( View Tweet)
#RA with ILD portends poor outcomes, especially if seropositive. Visiting professor Dr. Jeff sparks @jeffsparks @UTSW_Rheum https://t.co/fbVyDMUm6L
Dr. John Cush RheumNow ( View Tweet)
Rheumatologist - Work-Life Survey Results
Last week, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
https://t.co/2g7oL6ltAo https://t.co/uYv7sDyO9o
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now.
https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 42 pts w/ cocaine-induced midline or systemic vasculitis; Current cocaine use common (20/23 + urine tox, including pts who prev. deniedcocaine). Found: septal perfs (75%), oronasal fistula(15%), less(27%) systemic Sxs, 56% PR3-ANCA+https://t.co/z1Z4INRSj5 https://t.co/v9ZyZD1Lrb
Links:
Dr. John Cush RheumNow ( View Tweet)
With AI and GPT-4... "The cognitive speed limit has just been lifted." - John Nosta https://t.co/mMXos8LLt6 https://t.co/imBfp37J1l
Links:
Dr. John Cush RheumNow ( View Tweet)
Spanish Society of Rheumatology (SER) study finds w/ retirement of many older (male) Rheums; there are workforce shortages. Most (59.7%) of rheums in Spain are women, the majority below age 54 yrs. https://t.co/DPs0S63Aqc https://t.co/ig4kOQWmkn
Links:
Dr. John Cush RheumNow ( View Tweet)
vit D shows no change in Fx Risk. Study of 20,326 Australians given placebo or vit D3 60K IU/mo. 46% women, age 69 yrs. W/ 5.1 yrs F/U - no effect on Fx risk (HR 0·94; 0·84–1·06). Fx in 5.6% of Vit D vs 5.9% in PBO (non-vertebral, major OP & hip Fxs https://t.co/cSbTS3xWrX https://t.co/Jipzw28Wn8
Links:
Dr. John Cush RheumNow ( View Tweet)
Antiphospholipid Antibodies With Incident Cardiovascular Events
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?
https://t.co/XQk17P6D2f https://t.co/y5exrsicW8
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumThoughts: Changing the Conversation with Patients: Lupus
Join the discussion! RheumThoughts are opinion pieces from healthcare professionals.
https://t.co/NcJcCZVlbE
@drbags71 https://t.co/VfAqUkqLak
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Presents Women In Rheumatology: Contract Negotiations https://t.co/nkAu5kQj2w
Dr. John Cush RheumNow ( View Tweet)
TONIGHT! Tuesday Night Rheumatology addresses Contract Negotiations, featuring Andrea Liberatore, JD, Gwenesta Melton, MD, and Kathryn Dao, MD.
Sign up to attend this and all of our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/L2WMLnnJhV https://t.co/Z4kEBJHBjz
Links:
Dr. John Cush RheumNow ( View Tweet)
Probiotic strain Ligilactobacillus salivarius studied in gout (as it metabolizes purines). 30 pts w/ hyperuricemia & recurrent gout were given L. salivarius or allopurinol for 6 mos. Probiotic group had less gout attacks (5/15) than controls (13/15). https://t.co/njPZdKhBxv https://t.co/YO27M8p5Ki
Links:
Dr. John Cush RheumNow ( View Tweet)